◎ Sugi Atlas

Atlas / Drug / Durvalumab

Durvalumab

drug
On this page

Also known as ImfinziMEDI-4736MEDI4736

Summary

Durvalumab (CHEMBL3301587) is an approved antibody (ATC L01FF03); indicated across 97 conditions including neoplasm and non-small cell lung carcinoma; with CIViC clinical evidence for 10 variant-indication associations (e.g. CD274 Amplification in triple-receptor negative breast cancer).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Antibody
  • ATC class: L01FF03
  • Indications: 97 conditions
  • Clinical trials: 719
  • Precision-oncology evidence (CIViC): 10 variant–indication associations

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL3301587
NameDurvalumab
TypeAntibody
Max phase4
ATCL01FF03

Also known as: Durvalumab, Imfinzi, MEDI-4736, MEDI4736, DURVALUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

97 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm4MONDO:0005070EFO:0000616
non-small cell lung carcinoma4MONDO:0005233EFO:0003060
small cell lung carcinoma4MONDO:0008433EFO:0000702
breast carcinoma3MONDO:0004989EFO:0000305
breast neoplasm3MONDO:0021100EFO:0003869
head and neck squamous cell carcinoma3MONDO:0010150EFO:0000181
ovarian carcinoma3MONDO:0005140EFO:0001075
squamous cell lung carcinoma3MONDO:0005097EFO:0000708
mesothelioma3MONDO:0005065EFO:0000588
hepatocellular carcinoma3MONDO:0007256EFO:0000182
urinary bladder neoplasm3MONDO:0004987EFO:0000294
clear cell renal carcinoma3MONDO:0005005EFO:0000349
renal cell carcinoma3MONDO:0005086EFO:0000681
squamous cell carcinoma3MONDO:0005096EFO:0000707
biliary tract neoplasm3MONDO:0005304EFO:0003891
esophageal squamous cell carcinoma3MONDO:0005580EFO:0005922
oropharynx cancer3MONDO:0004608EFO:1001931
urothelial carcinoma3MONDO:0040679EFO:0008528
malignant pleural mesothelioma3MONDO:0005112EFO:0000770
endometrium neoplasm3MONDO:0021251EFO:0004230
ovarian cancer3MONDO:0008170MONDO:0008170
lung neoplasm3MONDO:0021117MONDO:0008903
papillary renal cell carcinoma3MONDO:0017884EFO:0000640
lung carcinoma3MONDO:0005138EFO:0001071
gastric adenocarcinoma2MONDO:0005036EFO:0000503
melanoma2MONDO:0005105EFO:0000756
diffuse large B-cell lymphoma2MONDO:0018905EFO:0000403
glioblastoma2MONDO:0018177EFO:0000519
plasma cell myeloma2MONDO:0009693EFO:0001378
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
myelodysplastic syndrome2MONDO:0018881EFO:0000198
acute myeloid leukemia2MONDO:0018874EFO:0000222
adenocarcinoma2MONDO:0004970EFO:0000228
clear cell adenocarcinoma2MONDO:0005004EFO:0000348
germ cell tumor2MONDO:0005040EFO:0000514
lymphoma2MONDO:0005062EFO:0000574
sarcoma2MONDO:0005089EFO:0000691
lung large cell carcinoma2MONDO:0003050EFO:0003050
upper aerodigestive tract neoplasm2MONDO:0005398EFO:0004284
non-Hodgkin lymphoma2MONDO:0018908EFO:0005952
head and neck cancer2MONDO:0005627EFO:0006859
rectal cancer2MONDO:0006519EFO:1000657
colorectal carcinoma2MONDO:0024331EFO:1001951
thyroid gland follicular carcinoma2MONDO:0005034EFO:0000501
lung adenocarcinoma2MONDO:0005061EFO:0000571
thyroid gland papillary carcinoma2MONDO:0005075EFO:0000641
prostate adenocarcinoma2MONDO:0005082EFO:0000673
triple-negative breast carcinoma2MONDO:0005494EFO:0005537
fallopian tube carcinoma2MONDO:0006206EFO:1000251
colorectal adenocarcinoma2MONDO:0005008EFO:0000365
angiosarcoma2MONDO:0016982EFO:0003968
lung neuroendocrine neoplasm2MONDO:0005454EFO:0005220
cholangiocarcinoma2MONDO:0019087EFO:0005221
intrahepatic cholangiocarcinoma2MONDO:0003210EFO:1001961
soft tissue sarcoma2MONDO:0018078EFO:1001968
gastric neoplasm2MONDO:0021085MONDO:0001056
seminoma2MONDO:0003001MONDO:0003001
dysgerminoma2MONDO:0003002MONDO:0003002
bile duct neoplasm2MONDO:0021662MONDO:0003059
anus neoplasm2MONDO:0003046MONDO:0003199
oral cavity squamous cell carcinoma2MONDO:0004958EFO:0000199
colonic neoplasm2MONDO:0005401MONDO:0021063
inflammatory breast carcinoma2MONDO:0006804EFO:1000984
prostate carcinoma2MONDO:0005159EFO:0001663
pancreatic neoplasm2MONDO:0021040EFO:0003860
chronic hepatitis B virus infection2MONDO:0005366EFO:0004239
gallbladder neoplasm2MONDO:0021253EFO:0004606
female reproductive organ cancer2MONDO:0001416EFO:1001331
gallbladder carcinoma2MONDO:0003220EFO:1001956
neuroendocrine carcinoma2MONDO:0002120MONDO:0002120
pancreatic ductal adenocarcinoma2MONDO:0005184MONDO:0005184
colorectal neoplasm2MONDO:0005335MONDO:0005575
rectal neoplasm2MONDO:0002165MONDO:0044937
primary myelofibrosis1MONDO:0009692EFO:0002430
B-cell chronic lymphocytic leukemia1MONDO:0004948EFO:0000095
acquired polycythemia vera1MONDO:0009891EFO:0002429
primary cutaneous T-cell non-Hodgkin lymphoma1MONDO:0000607EFO:0002913
plasmacytoma1MONDO:0005615EFO:0006738
metastatic neoplasm1MONDO:0024883EFO:0009709
follicular lymphoma1MONDO:0018906MONDO:0018906
skin neoplasm1MONDO:0002531MONDO:0002898

16 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 719.

Phase distribution

PhaseTrials
PHASE2380
PHASE1125
PHASE1/PHASE288
PHASE387
Not specified20
EARLY_PHASE19
PHASE45
PHASE2/PHASE35

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06031233PHASE4RECRUITINGEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
NCT06908070PHASE4RECRUITINGChemoradiotherapy With Surgery Followed by Consolidation Durvalumab
NCT04078152PHASE4COMPLETEDDurvalumab Long-Term Safety and Efficacy Study
NCT04356222PHASE4UNKNOWNEfficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
NCT04416633PHASE4COMPLETEDStudy to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC
NCT02273375PHASE3ACTIVE_NOT_RECRUITINGDouble Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
NCT02453282PHASE3ACTIVE_NOT_RECRUITINGPhase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
NCT02516241PHASE3ACTIVE_NOT_RECRUITINGStudy of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
NCT02542293PHASE3ACTIVE_NOT_RECRUITINGStudy of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
NCT03003962PHASE3ACTIVE_NOT_RECRUITINGStudy of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
NCT03043872PHASE3ACTIVE_NOT_RECRUITINGDurvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
NCT03164616PHASE3ACTIVE_NOT_RECRUITINGStudy of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
NCT03288532PHASE3RECRUITINGRenal Adjuvant MultiPle Arm Randomised Trial
NCT03298451PHASE3ACTIVE_NOT_RECRUITINGStudy of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT03519971PHASE3ACTIVE_NOT_RECRUITINGStudy of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
NCT03528694PHASE3ACTIVE_NOT_RECRUITINGAssessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
NCT03682068PHASE3ACTIVE_NOT_RECRUITINGStudy of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
NCT03703297PHASE3ACTIVE_NOT_RECRUITINGStudy of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT03706690PHASE3ACTIVE_NOT_RECRUITINGA Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
NCT03732677PHASE3ACTIVE_NOT_RECRUITINGDurvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
NCT03737643PHASE3ACTIVE_NOT_RECRUITINGDurvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
NCT03778957PHASE3ACTIVE_NOT_RECRUITINGA Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
NCT03800134PHASE3ACTIVE_NOT_RECRUITINGA Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
NCT03833154PHASE3ACTIVE_NOT_RECRUITINGDurvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
NCT03847428PHASE3ACTIVE_NOT_RECRUITINGAssess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
NCT03875235PHASE3ACTIVE_NOT_RECRUITINGDurvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
NCT04092283PHASE3ACTIVE_NOT_RECRUITINGTesting the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
NCT04116047PHASE3ACTIVE_NOT_RECRUITINGCompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
NCT04269200PHASE3ACTIVE_NOT_RECRUITINGDurvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
NCT04380636PHASE3ACTIVE_NOT_RECRUITINGStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
NCT04465968PHASE3NOT_YET_RECRUITINGEfficacy and Safety of CRT, Durvalumab and Surgery for SST
NCT04550260PHASE3ACTIVE_NOT_RECRUITINGStudy of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
NCT04585490PHASE3RECRUITINGPersonalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
NCT04592913PHASE3ACTIVE_NOT_RECRUITINGAssessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
NCT04597671PHASE3ACTIVE_NOT_RECRUITINGDurvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)
NCT04628767PHASE2/PHASE3RECRUITINGTesting the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
NCT04637594PHASE3ACTIVE_NOT_RECRUITINGTrying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
NCT04960709PHASE3ACTIVE_NOT_RECRUITINGTreatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
NCT05043090PHASE3ACTIVE_NOT_RECRUITINGSavolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
NCT05170204PHASE3ACTIVE_NOT_RECRUITINGA Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

Clinical evidence (CIViC)

Variant × indication × effect (10 predictive associations from 10 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
CD274 AmplificationTriple-receptor Negative Breast CancerSensitivity/ResponseDurvalumabCIViC BEID12054
CD274 ExpressionLung Non-small Cell CarcinomaSensitivity/ResponseAtezolizumab + Avelumab + Pembrolizumab + Nivolumab + DurvalumabCIViC BEID4857
PBRM1 Loss-of-functionRenal Cell CarcinomaSensitivity/ResponseAtezolizumab + DurvalumabCIViC BEID7537
TMB HighColorectal CancerSensitivity/ResponseTremelimumab + DurvalumabCIViC BEID12042
TMB HighLung Non-small Cell CarcinomaSensitivity/ResponseDurvalumab + TremelimumabCIViC BEID12799
TMB HighHead And Neck Squamous Cell CarcinomaSensitivity/ResponseDurvalumabCIViC BEID12850
MSH2 LossTransitional Cell CarcinomaSensitivity/ResponseAnti-PD-1 Monoclonal Antibody MEDI0680 + DurvalumabCIViC CEID1877
MSH6 LOSSTransitional Cell CarcinomaSensitivity/ResponseAnti-PD-1 Monoclonal Antibody MEDI0680 + DurvalumabCIViC CEID1878
EGFR E746_A750delLung Non-small Cell CarcinomaSensitivity/ResponseDurvalumabCIViC DEID2518
CD274 v242Lung Non-small Cell CarcinomaResistanceDurvalumab + Atezolizumab + AvelumabCIViC EEID9695

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 15

This page pulls from 15 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_interactiongtopdb_ligandmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchem